tremelimumab,durvalumab,Sorafenib
AstraZeneca,Pfizer
['tremelimumab', 'durva']
patients with unresectable hepatocellular carcinoma experienced manageable and low-grade immune-related adverse events with single tremelimumab regular interval durvalumab. #asco23 #asco2023 #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.